Amyloid imaging in atypical presentations of Alzheimer's disease

Current Neurology and Neuroscience Reports

Volumn 13, Issue 12, 2013, Pages

  Wolk, David A ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Amyloid imaging; Atypical dementia; Frontal variant of Alzheimer's disease; Logopenic progressive aphasia; Posterior cortical atrophy

Indexed keywords

PITTSBURGH COMPOUND B; AMYLOID;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; BRAIN CORTEX ATROPHY; DISEASE ASSOCIATION; ECHOLALIA; EPISODIC MEMORY; FRONTAL VARIANT OF ALZHEIMER DISEASE; HUMAN; LANGUAGE ABILITY; LOPOGENIC PROGRESSIVE APHASIA; NEUROFIBRILLARY TANGLE; NEUROIMAGING; ONSET AGE; PROGRESSIVE NONFLUENT APHASIA; SEMANTIC DEMENTIA; WORKING MEMORY; AGED; ATROPHY; BRAIN CORTEX; FRONTOTEMPORAL DEMENTIA; METABOLISM; METHODOLOGY; PATHOLOGY; PRIMARY PROGRESSIVE APHASIA; REVIEW;

AGED; ALZHEIMER DISEASE; AMYLOID; APHASIA, PRIMARY PROGRESSIVE; ATROPHY; CEREBRAL CORTEX; FRONTOTEMPORAL DEMENTIA; HUMANS; NEUROIMAGING;

EID: 84890487208     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-013-0412-x     Document Type: Article

References (64)

1. •• McKhann G, Drachman D, Folstein M, Katzman R, Price D. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:285-97.
2. van der Flier WM, Pijnenburg YA, Fox NC, Scheltens P. Early-onset versus late-onset Alzheimer's disease: the case of the missing APOE ε4 allele. Lancet Neurol. 2011;10(3):280-8.
3. Snowden JS, Stopford CL, Julien CL, et al. Cognitive phenotypes in Alzheimer's disease and genetic risk. Cortex. 2007;43(7):835-45.
4. Wolk DA, Dickerson BC. Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer's disease. Proc Natl Acad Sci U S A. 2010;107(22):10256-61.
5. Murray ME, Graff-Radford NR, Ross OA, Petersen RC, Duara R, Dickson DW. Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. Lancet Neurol. 2011;10(9):785-96.
6. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):263-9.
7. Mesulam M, Wicklund A, Johnson N, et al. Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia. Ann Neurol. 2008;63(6):709-19.
8. • Gorno-Tempini ML, Hillis AE, Weintraub S, et al. Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006-14. This article describes recently proposed criteria for different variants of PPA, which are probabilistically associated with different pathologic causes.
9. Hyman BT, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement. 2012;8(1):1-13.
10. Jack Jr CR, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207-16.
11. Carrillo MC, Brashear HR, Logovinsky V, et al. Can we prevent Alzheimer's disease? Secondary prevention trials in Alzheimer's disease. Alzheimers Dement. 2013;9(2):123-31.e1.
12. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-B. Ann Neurol. 2004;55(3):306-19.
13. Roe CM, Fagan AM, Grant EA, et al. Amyloid imaging and CSF biomarkers in predicting cognitive impairment up to 7.5 years later. Neurology. 2013;80(19):1784-91.
14. Wolk DA, Price JC, Saxton JA, et al. Amyloid imaging in mild cognitive impairment subtypes. Ann Neurol. 2009;65(5):557-68.
15. Ikonomovic MD, Klunk WE, Abrahamson EE, et al. Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease. Brain. 2008;131(6):1630-45.
16. Rowe CC, Villemagne VL. Amyloid imaging with PET in early Alzheimer disease diagnosis. Med Clin N Am. 2013;97(3):377-98.
17. Wolk DA, Grachev ID, Buckley C, et al. Association between in vivo fluorine 18-labeled flutemetamol amyloid positron emission tomography imaging and in vivo cerebral cortical histopathology. Arch Neurol. 2011;68(11):1398-403.
18. • Clark CM, Schneider JA, Bedell BJ, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011;305(3):275-83. This is a landmark article demonstrating strong concordance of in vivo amyloid imaging of florbetapir PET with ex vivo amyloid plaque pathology. These data provide strong support for the validity of this imaging method.
19. Rowe CC, Ackerman U, Browne W, et al. Imaging of amyloid beta in Alzheimer's disease with 18F-BAY94-9172, a novel PET tracer: proof of mechanism. Lancet Neurol. 2008;7(2):129-35.
20. Hodges JR, Patterson K, Oxbury S, Funnell E. Semantic dementia. Progressive fluent aphasia with temporal lobe atrophy. Brain. 1992;115(6):1783-806.
21. Grossman M. The non-fluent/agrammatic variant of primary progressive aphasia. Lancet Neurol. 2012;11(6):545-55.
22. Josephs KA. Frontotemporal dementia and related disorders: deciphering the enigma. Ann Neurol. 2008;64(1):4-14.
23. Davies RR, Hodges JR, Kril JJ, Patterson K, Halliday GM. Xuereb JH The pathological basis of semantic dementia. Brain. 2005;128(9):1984-95.
24. Grossman M, Wood EM, Moore P, et al. TDP-43 pathologic lesions and clinical phenotype in frontotemporal lobar degeneration with ubiquitin-positive inclusions. Arch Neurol. 2007;64(10):1449-54.
25. • Grossman M. Primary progressive aphasia: clinicopathological correlations. Nat Rev Neurol. 2010;6(2):88-97. This is an excellent review of PPAs and a summary of the pathology data associated with each variant.
26. Knibb JA, Xuereb JH, Patterson K. Hodges JR Clinical and pathological characterization of progressive aphasia. Ann Neurol. 2006;59(1):156-65.
27. Gorno-Tempini ML, Dronkers NF, Rankin KP, et al. Cognition and anatomy in three variants of primary progressive aphasia. Ann Neurol. 2004;55(3):335-46.
28. Rabinovici GD, Jagust WJ, Furst AJ, et al. Aβ amyloid and glucose metabolism in three variants of primary progressive aphasia. Ann Neurol. 2008;64(4):388-401.
29. Mesulam M, Wieneke C, Rogalski E, Cobia D, Thompson C, Weintraub S. Quantitative template for subtyping primary progressive aphasia. Arch Neurol. 2009;66(12):1545-51.
30. Leyton CE, Villemagne VL, Savage S, et al. Subtypes of progressive aphasia: application of the international consensus criteria and validation using beta-amyloid imaging. Brain. 2011;134(10):3030-43.
31. • Wolk DA, Price JC, Madeira C, et al. Amyloid imaging in dementias with atypical presentation. Alzheimers Dement. 2012;8(5):389-98. This is a case series demonstrating the potential clinical value of amyloid imaging in atypical, or difficult to diagnosis, dementia. These data support the clinical heterogeneity by which AD presents.
32. •• Lehmann M, Ghosh PM, Madison C, et al. Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer's disease. Brain. 2013;136(3):844-58. This is an excellent study describing dissociations between network-level abnormalities of glucose metabolism and PiB uptake in LPA (n = 12), PCA (n = 13), and early onset AD (n = 17). Although there was some suggestion of more focal PiB uptake in the visual association network of PCA patients, abnormalities in patterns of metabolism mapped much more clearly onto expected networks of impairment for these conditions than amyloid distribution measured by PiB PET.
33. Arriagada PV, Growdon JH, Hedley-Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology. 1992;42:631-9.
34. Green J, Morris JC, Sandson J, McKeel Jr DW, Miller JW. Progressive aphasia: a precursor of global dementia? Neurology. 1990;40(3 Pt 1):423-9.
35. Galton CJ, Patterson K, Xuereb JH, Hodges JR. Atypical and typical presentations of Alzheimer's disease: a clinical, neuropsychological, neuroimaging and pathological study of 13 cases. Brain. 2000;123(3):484-98.
36. Alladi S, Xuereb J, Bak T, et al. Focal cortical presentations of Alzheimer's disease. Brain. 2007;130(10):2636-45.
37. Cogan DG. Visual disturbances with focal progressive dementing disease. Am J Ophthalmol. 1985;100(1):68-72.
38. Benson DF, Davis RJ, Snyder BD. Posterior cortical atrophy. Arch Neurol. 1988;45(7):789-93.
39. McMonagle P, Deering F, Berliner Y, Kertesz A. The cognitive profile of posterior cortical atrophy. Neurology. 2006;66(3):331-8.
40. • Crutch SJ, Schott JM, Rabinovici GD, et al. Shining a light on posterior cortical atrophy. Alzheimers Dement. 2013;9(4):463-5. This is an excellent review of the syndrome of PCA and unresolved clinical and research issues related to this diagnosis.
41. Nestor PJ, Caine D, Fryer TD, Clarke J, Hodges JR. The topography of metabolic deficits in posterior cortical atrophy (the visual variant of Alzheimer's disease) with FDG-PET. J Neurol Neurosurg Psychiatry. 2003;74(11):1521-9.
42. Tang-Wai DF, Graff-Radford NR, Boeve BF, et al. Clinical, genetic, and neuropathologic characteristics of posterior cortical atrophy. Neurology. 2004;63(7):1168-74.
43. Mendez MF, Ghajarania M, Perryman KM. Posterior cortical atrophy: clinical characteristics and differences compared to Alzheimer's disease. Dement Geriatr Cogn Disord. 2002;14(1):33-40.
44. Renner JA, Burns JM, Hou CE, McKeel Jr DW, Storandt M, Morris JC. Progressive posterior cortical dysfunction: a clinicopathologic series. Neurology. 2004;63(7):1175-80.
45. Hof PR, Bouras C, Constantinidis J, Morrison JH. Balint's syndrome in Alzheimer's disease: specific disruption of the occipito-parietal visual pathway. Brain Res. 1989;493(2):368-75.
46. Hof PR, Archin N, Osmand AP, et al. Posterior cortical atrophy in Alzheimer's disease: analysis of a new case and re-evaluation of a historical report. Acta Neuropathol. 1993;86(3):215-23.
47. Rosenbloom MH, Alkalay A, Agarwal N, et al. Distinct clinical and metabolic deficits in PCA and AD are not related to amyloid distribution. Neurology. 2011;76(21):1789-96.
48. Ng SY, Villemagne VL, Masters CL, Rowe CC. Evaluating atypical dementia syndromes using positron emission tomography with carbon 11 labeled Pittsburgh compound B. Arch Neurol. 2007;64(8):1140-4.
49. Tenovuo O, Kemppainen N, Aalto S, Nagren K, Rinne JO. Posterior cortical atrophy: a rare form of dementia with in vivo evidence of amyloid-beta accumulation. J Alzheimers Dis. 2008;15(3):351-5.
50. Migliaccio R, Agosta F, Rascovsky K, et al. Clinical syndromes associated with posterior atrophy: early age at onset AD spectrum. Neurology. 2009;73(19):1571-8.
51. • de Souza LC, Corlier F, Habert MO, et al. Similar amyloid-beta burden in posterior cortical atrophy and Alzheimer's disease. Brain. 2011;134(7):2036-43. This is the largest case series of PCA patients (n = 9) who underwent amyloid imaging. This study did not reveal a different pattern of PiB uptake relative to that in typical AD.
52. Formaglio M, Costes N, Seguin J, et al. In vivo demonstration of amyloid burden in posterior cortical atrophy: a case series with PET and CSF findings. J Neurol. 2011;258(10):1841-51.
53. Gomperts SN, Locascio JJ, Marquie M, et al. Brain amyloid and cognition in Lewy body diseases. Mov Disord. 2012;27(8):965-73.
54. Binetti G, Magni E, Padovani A, Cappa SF, Bianchetti A, Trabucchi M. Executive dysfunction in early Alzheimer's disease. J Neurol Neurosurg Psychiatry. 1996;60(1):91-3.
55. Mega MS, Cummings JL, Fiorello T, Gornbein J. The spectrum of behavioral changes in Alzheimer's disease. Neurology. 1996;46(1):130-5.
56. Woodward M, Jacova C, Black SE, Kertesz A, Mackenzie IR, Feldman H. Differentiating the frontal variant of Alzheimer's disease. Int J Geriatr Psychiatry. 2010;25(7):732-8.
57. Johnson JK, Head E, Kim R, Starr A, Cotman CW. Clinical and pathological evidence for a frontal variant of Alzheimer disease. Arch Neurol. 1999;56(10):1233-9.
58. Forman MS, Farmer J, Johnson JK, et al. Frontotemporal dementia: clinicopathological correlations. Ann Neurol. 2006;59(6):952-62.
59. Lehmann M, Madison CM, Ghosh PM, et al. Intrinsic connectivity networks in healthy subjects explain clinical variability in Alzheimer's disease. Proc Natl Acad Sci U S A. 2013;110(28):11606-11.
60. Pa J, Boxer A, Chao LL, et al. Clinical-neuroimaging characteristics of dysexecutive mild cognitive impairment. Ann Neurol. 2009;65(4):414-23.
61. Johnson JK, Vogt BA, Kim R, Cotman CW, Head E. Isolated executive impairment and associated frontal neuropathology. Dement Geriatr Cogn Disord. 2004;17(4):360-7.
62. Rabinovici GD, Furst AJ, O'Neil JP, et al. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration. Neurology. 2007;68(15):1205-12.
63. Lopez OL, Becker JT, Klunk W, et al. Research evaluation and diagnosis of probable Alzheimer's disease over the last two decades: I. Neurology. 2000;55(12):1854-62.
64. •• Johnson KA, Minoshima S, Bohnen NI, et al. Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association. Alzheimers Dement. 2013;9(1):E1-16. This article describes a proposal for the appropriate use of amyloid PET in clinical practice. Of relevance to the current discussion, amyloid imaging was argued to be of particular value in atypical or early onset cases, such as those described here.